eFFECTOR Therapeutics, Inc.

eFFECTOR Therapeutics, Inc. (Nasdaq: EFTR) is a clinical-stage biopharmaceutical company focused on selective translation regulator inhibitors targeting oncology indications. The company became publicly listed in 2021 through a SPAC business combination with Locust Walk Acquisition Corp, a blank-check vehicle sponsored by Locust Walk, a life-sciences-focused advisory and investment firm. The June 2024 Form 8-K filing reflects continued post-merger reporting obligations as eFFECTOR advances its pipeline programs in the oncology space. The company operates in the healthcare and biotechnology sector, with its clinical candidates centered on disrupting cancer cell translation machinery. Sign up at SpacDesk for full filing history, sponsor profiles, and real-time deal intelligence on eFFECTOR and hundreds of other SPAC transactions.